Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study

ABSTRACT

Background: Validation of cognitive instruments for detection of Alzheimer's disease (AD) based on correlation with diagnostic biomarkers allows more reliable identification of the disease.

Objectives: To investigate the accuracy of the Brief Cognitive Screening Battery (BCSB) in the differential diagnosis between AD, non-AD cognitive impairment (both defined by cerebrospinal fluid [CSF] biomarkers) and healthy cognition, and to correlate CSF biomarker results with cognitive performance. Methods: Overall, 117 individuals were evaluated: 45 patients with mild cognitive impairment (MCI) or mild dementia within the AD continuum defined by the AT(N) classification [A+T+/-(N)+/]; 27 non-AD patients with MCI or mild dementia [A-T+/-(N)+/-]; and 45 cognitively healthy individuals without CSF biomarker results. All participants underwent evaluation using the BCSB. Results: The total BCSB and delayed recall (DR) scores of the BCSB memory test showed high diagnostic accuracy, as indicated by areas under the ROC curve (AUC): 0.89 and 0.87, respectively, for discrimination between AD and non-AD versus cognitively healthy controls. Similarly, total BCSB and DR displayed high accuracy (AUC-ROC curves of 0.89 and 0.91, respectively) for differentiation between AD and controls. BCSB tests displayed low accuracy for differentiation between AD and non-AD. The CSF levels of biomarkers correlated significantly, though weakly, with DR. Conclusions: Total BCSB and DR scores presented good accuracy for differentiation between patients with a biological AD diagnosis and cognitively healthy individuals, but low accuracy for differentiating AD from non-AD patients.

RESUMO

Antecedentes: A validação de testes cognitivos para identificação da doença de Alzheimer (DA) definida por biomarcadores aumenta a confiabilidade diagnóstica.

Objetivos: Investigar a acurácia da Bateria Breve de Rastreio Cognitivo (BBRC) no diagnóstico diferencial entre DA, comprometimento cognitivo não-DA (ambos diagnósticos definidos por biomarcadores no líquido cefalorraquidiano-LCR) e indivíduos cognitivamente saudáveis, e investigar correlações entre desempenho nos testes e concentrações dos biomarcadores no LCR. Métodos: No total, 117 indivíduos foram avaliados. Quarenta e cinco pacientes com comprometimento cognitivo leve (CCL) ou demência leve com diagnóstico do continuum de DA definido pela classificação AT(N) [A+T+/-(N)+/-], 27 pacientes com CCL ou demência leve não-DA [A-T+/-(N)+/-], e 45 controles cognitivamente saudáveis sem estudo de biomarcadores no LCR. Os participantes foram submetidos à BBRC. Resultados: O escore total da BBRC e a evocação tardia (ET) no teste de memória da BBRC apresentaram elevada acurácia diagnóstica na diferenciação entre DA e não-DA versus controles, indicada pelas áreas sob a curva ROC (AUC) de 0,89 e 0,87, respectivamente. De modo semelhante, o escore total da BBRC e a ET mostraram elevadas acurácias (AUC-ROC de 0,89 e 0,91, respectivamente) para o diagnóstico diferencial entre DA e controles. A acurácia da BBRC foi baixa na diferenciação entre DA e não-DA. Os níveis dos biomarcadores no LCR se correlacionaram de forma significativa, embora fraca, com ET. Conclusões: Os escores totais da BCSB e a ET apresentaram boa acurácia na diferenciação entre pacientes com diagnóstico biológico de DA e controles cognitivamente saudáveis, mas baixa acurácia para diferenciar DA de não-DA.

Keywords:

Alzheimer Disease - Cognitive Dysfunction - Diagnosis - Biomarkers - Cognition

Palavras-chave:

Doença de Alzheimer - Disfunção Cognitiva - Diagnóstico - Biomarcadores - Cognição

• References

• 1 Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 9503 2112-2117 https://doi.org/10.1016/S0140-6736(05)67889-0
• 2 Fiest KM, Jetté N, Roberts JI, Maxwell CJ, Smith EE, Black SE. et al. The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci 2016; 43 (Suppl. 01) S3-50 https://doi.org/10.1017/cjn.2016.18
• 3 The Lancet. Alzheimer's disease: expedition into the unknown. Lancet 2016; 388: 10061-2713 https://doi.org/10.1016/S0140-6736(16)32457-6
• 4 Herrera Jr E, Caramelli P, Silveira ASB, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2002; 16 (02) 103-108 https://doi.org/10.1097/00002093-200204000-00007
• 5 Nitrini R, Bottino CM, Albala C, Capuñay NSC, Ketzoian C, Rodriguez JJL. et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. Int Psychogeriatr 2009; 21 (04) 622‐30-622‐30 https://doi.org/10.1017/S1041610209009430
• 6 Callahan CM, Tu W, Stump TE, Clark DO, Unroe KT, Hendrie HC. Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs. Alzheimer Dis Assoc Disord 2015; 29 (01) 75‐81-75‐81 https://doi.org/10.1097/WAD.20210012202100120048
• 7 Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC. et al. Introduction to the recommendations of the National Institute on Aging-Alzheimer's Association working groups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (03) 257-262 https://doi.org/10.1016/j.jalz.2011.03.004
• 8 Nitrini R, Caramelli P, Bottino CMC, Damasceno BP, Brucki SMD, Anghinah R. Academia Brasileira de Neurologia Diagnosis of Alzheimer's disease in Brazil: diagnostic criteria and auxiliary tests. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 2005; 63 3A 713-719 https://doi.org/10.1590/S0004-282X2005000400033
• 9 Nitrini R, Lefèvre BH, Mathias SC, Caramelli P, Carrilho PE, Sauaia N. et al. Neuropsychological tests of simple application for diagnosing dementia. Arq Neuropsiquiatr 1994; 52 (04) 457-465 https://doi.org/10.1590/S0004-282X1994000400001
• 10 Yassuda MS, Silva HS, Lima-Silva TB, Cachioni M, Falcão DVS, Lopes A. et al. Normative data for the brief cognitive screening battery stratified by age and education. Dement Neuropsychol 2017; 11 (01) 48-53 https://doi.org/10.1590/1980-57642016dn11-010008
• 11 Nitrini R, Caramelli P, Porto CS, Charchat-Fichman H, Formigoni AP, Carthery-Goulart MT. et al. Brief cognitive battery in the diagnosis of mild alzheimer's disease in subjects with medium and high levels of education. Dement Neuropsychol 2007; 1 (01) 32-36 https://doi.org/10.1590/S1980-57642008DN10100006
• 12 Fichman-Charchat H, Miranda CV, Fernandes CS, Mograbi D, Oliveira RM, Novaes R. et al. Brief Cognitive Screening Battery (BCSB) is a very useful tool for diagnosis of probable mild Alzheimer´s disease in a geriatric clinic. Arq Neuropsiquiatr 2016; 74 (02) 149-154 https://doi.org/10.1590/0004-282X20150202
• 13 Folstein M, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (03) 189-198 https://doi.org/10.1016/0022-3956(75)90026-6
• 14 Bertolucci PHF, Brucki SMD, Campacci SR, Juliano Y. The Mini-Mental State Examination in a general population: impact of educational status. Arq Neuropsiquiatr 1994; 52 (01) 1-7 https://doi.org/10.1590/S0004-282X1994000100001
• 15 Albert MS, DeKosky ST, Dickson DW, Dubois B, Feldman HH, Fox NC. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations by the National Institute on Aging-Alzheimer's Association working groups on diagnostic guidelines for alzheimer's disease. Alzheimers Dement 2011; 7 (03) 270-279 https://doi.org/10.1016/j.jalz.2011.03.008
• 16 McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH. et al. The diagnosis of dementia due to alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for alzheimer's disease. Alzheimers Dement 2011; 7 (03) 263-269 https://doi.org/10.1016/j.jalz.2011.03.005
• 17 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134 (09) 2456-2477 https://doi.org/10.1093/brain/awr179
• 18 Román GC. Defining dementia: clinical criteria for the diagnosis of vascular dementia. Acta Neurol Scand Suppl 2002; 106 (178) 6-9 https://doi.org/10.1034/j.1600-0404.106.s178.2.x
• 19 Wetterling T, Kanitz RD, Borgis KJ. Clinical evaluation of the ICD-10 criteria for vascular dementia. Eur Arch Psychiatry Clin Neurosci 1993; 243 (01) 33-40 https://doi.org/10.1007/BF02191521
• 20 Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF. et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76 (11) 1006-1014 https://doi.org/10.1212/WNL.0b013e31821103e6
• 21 McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA. et al. Consensus guidelines for the clinical and pathologic diagnosis of Dementia with Lewy Bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47 (05) 1113-1124 https://doi.org/10.1212/WNL.47.5.1113
• 22 Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose Dementia with Lewy Bodies: state of the art. Mov Disord 2005; 20 (Suppl. 12) S11-S20 https://doi.org/10.1002/mds.20535
• 23 Amaral-Carvalho V, Caramelli P. Normative data for healthy middle-aged and elderly performance on the Addenbrooke Cognitive Examination-Revised. Cogn Behav Neurol 2012; 25 (02) 72-76 https://doi.org/10.1097/WNN.0b013e318259594b
• 24 Nitrini R, Lefèvre BH, Mathias SC, Caramelli P, Carrilho PE, Sauaia N. et al. Neuropsychological tests of simple application for diagnosing dementia. Arq Neuropsiquiatr 1994; 52 (04) 457‐65-457‐65 https://doi.org/10.1590/S0004-282X1994000400001
• 25 Brucki SM, Malheiros SM, Okamoto IH, Bertolucci PH. Normative data on the verbal fluency test in the animal category in our milieu. Arq Neuropsiquiatr 1997; 55 (01) 56-61 https://doi.org/10.1590/S0004-282X1997000100009
• 26 Shulman K, Gold DP, Cohen CA, Zuchero CA. Clock design and dementia in the community: a longitudinal study. Int J Geriatr Psych 1993; 8 (06) 487-496 https://doi.org/10.1002/gps.930080606
• 27 Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Dalaby C. et al. Impact of harmonization of collection tubes on alzheimer's disease diagnosis. Alzheimers Dement 2014; 10 (Suppl. 05) S390 94.e2 https://doi.org/10.1016/j.jalz.2013.06.008
• 28 Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I. et al. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement 2018; 14 (04) 492-501 https://doi.org/10.1016/j.jalz.2017.11.015
• 29 Bertoux M, Cassagnaud P, Lebouvier T, Lebert F, Sarazin M, Le Ber I. et al. Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. Neurobiol Aging 2020; 95: 123-130 https://doi.org/10.1016/j.neurobiolaging.2020.07.011
• 30 Bertoux M, Cassagnaud P, Lebouvier T, Lebert F, Sarazin M, Le Ber I. et al. Does amnesia specifically predict alzheimer's pathology? A neuropathological study. Neurobiol Aging 2020; 95: 123-130 https://doi.org/10.1016/j.neurobiolaging.2020.07.011
• 31 Nitrini R, Caramelli P, Herrera Júnior E, Porto CS, Charchat-Fichman H, Carthery MT. et al. Performance of illiterate and literate nondemented elderly subjects in two tests of long-term memory. J Int Neuropsychol Soc 2004; 10 (04) 634-638 https://doi.org/10.1017/S1355617704104062
• 32 Takada LT, Caramelli P, Fichman HC, Porto CS, Bahia VS, Anghinah R. et al. Comparison between two tests of delayed recall for the diagnosis of dementia. Arq Neuropsiquiatr 2006; 64 (01) 35-40 https://doi.org/10.1590/S0004-282X2006000100008
• 33 Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G. et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD): Part 1. Clinical and neuropsychological assessment of alzheimer's disease. Neurology 1989; 39 (09) 1159-1165 https://doi.org/10.1590/s0004-282x2006000100008
• 34 Bertolucci PH, Okamoto IH, Brucki SM, Siviero MO, Toniolo Neto J, Ramos LR. Applicability of the CERAD neuropsychological battery to Brazilian elderly. Arq Neuropsiquiatr 2001; 59 3-A 532-536 https://doi.org/10.1590/S0004-282X2001000400009
• 35 Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H. et al. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 2011; 26 (01) 135-142 https://doi.org/10.3233/JAD-2011-110038
• 36 Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis 2013; 34 (04) 949-956 https://doi.org/10.3233/JAD-121960
• 37 Radanovic M, Oshiro CA, Freitas TQ, Talib LL, Forlenza OV. Correlation between biomarkers in the CSF of Alzheimer's disease and global cognition in a cohort of psychogeriatric clinic. Braz J Psychiatry 2019; 41 (06) 479-484 https://doi.org/10.1590/1516-4446-2018-0296
• 38 Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P. et al. Combining cerebrospinal fluid biomarkers and neuropsychological assessment: a simple and economical algorithm to predict the progression of cognitive impairment leading to Alzheimer's disease dementia. J Alzheimers Dis 2016; 54 (04) 1495-1508 https://doi.org/10.3233/JAD-160360
• 39 Ferreira D, Perestelo-Pérez L, Westman E, Wahlund L-O, Sarría A, Serrano-Aguilar P. Meta-review of central CSF biomarkers in Alzheimer's disease: the state of the art after the new diagnostic criteria reviewed. Front Aging Neurosci 2014; 6: 47 https://doi.org/10.3389/fnagi.2014.00047